This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings ...
Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 million series D. The round was co-led by investors Frazier Life Sciences and ...
Sanofi is offering up to $750 million in upfront cash and biobucks for Maze Therapeutics’ glycogen synthase 1 (GYS1) program, including a lead asset that’s recently completed a phase 1 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results